AbbVie says Stemcentrx’ stem cell drug shows some benefits in early trials
June 6, 2016Manufacturing and Production, Research and Development, Sales and Marketing ASCO, AbbVie, Stemcentrx, drug trial, lung cancer, rova-t
US drug firm AbbVie (NYSE: ABBV) said its early-stage trials for its drug to treat an aggressive form of lung …
Mylan’s breast cancer biosimilar matches Roche’s Herceptin in Phase III trial
June 6, 2016Research and Development ASCO, Biocon, Herceptin, Mylan, Roche, biosimilar, breast cancer, trastuzumab
Mylan (NASDAQ: MYL) and Biocon (NSE: BIOCON) have presented data the 2016 American Society of Clinical Oncology (ASCO) annual meeting …
Weekly Movers: Relypsa, Titan Pharma, Allergan…
June 6, 2016Research and Development, Sales and Marketing Stock, drug trial, research, stock market
The prestigious ASCO meet is underway and results of new drug trials will be a key stock mover over the …
Trial data shows promise for Lilly/MSD combo regimen in lung cancer
June 6, 2016Research and Development, Sales and Marketing MSD, Merck, collaboration, immuno-oncology, lilly, lung cancer, non-small cell, parternship
Eli Lilly (NYSE: LLY) has presented data at the American Society of Clinical Oncology (ASCO) annual congress showcasing its collaborations …
Bristol-Myers Squibb presents Opdivo data at ASCO
June 6, 2016Research and Development, Sales and Marketing ASCO, Bristol-Myers Squibb, opdivo
Bristol-Myers Squibb (NYSE: BMY) has presented a wide range of results on Opdivo (nivolumab) in a range of oncology indications …
Janssen says combination Phase III study for immunotherapy Darzalex for multiple myeloma shows significant PFS
June 6, 2016Research and Development, Sales and Marketing ASCO, Drig Trial, Janssen, multiple myeloma
Janssen said combination late stage trials for its immunotherapy drug to treat multiple myeloma showed 61% progression-free survival. The company …
Roche says Phase III trials for giant cell arteritis drug met primary endpoint
June 6, 2016Research and Development, Sales and Marketing Roche, arthritis, drug trial
Cancer drugmaker Roche (SIX: ROG) said late stage trials for its drug to treat giant cell arteritis (GCA) met its …
Sanofi and Regeneron combo shows superiority in late-stage atopic dermatitis trials
June 6, 2016Research and Development, Sales and Marketing Dupilumab, Regeneron, Sanofi, atopic dermatitis, late stage trials
Sanofi (NYSE: SNY) and Regeneron (NASDAQ: REGN) have announced positive results from a Phase III trial evaluating dupilumab in patients …
Novo Nordisk presents positive long-term results for Saxenda
June 3, 2016Medical Communications, Research and Development Novo Nordisk, cardiometabolic risk factors, liraglutide, saxenda, weight loss
Novo Nordisk has presented analysis covering three years of a late-stage trial for Saxenda (liarglutide 3mg) , which showed the …
Shire completes Baxalta takeover
June 3, 2016Medical Communications, Research and Development, Sales and Marketing Baxalta, Shire, deal, merger and acquisition, revenue, sales
UK drugmaker Shire (LSE: SHP) on Friday announced the completion of merger with rare disease specialist Baxalta (NYSE: BXLT). The …
Eisai partners with Novartis in renal cell carcinoma collaboration
June 3, 2016Medical Communications, Sales and Marketing Afinitor, Eisai, Lenvima, Novartis, US, everolimus, lenvatinib mesylate
Eisai (TYO: 4523) has announced that it has entered into a partnership with Novartis Pharmaceuticals to collaborate on commercial and …
Bayer, Orion to start Phase III trials for prostate cancer drug
June 3, 2016Medical Communications, Research and Development, Sales and Marketing Bayer, drug trial, orion, prostate cancer, research
German pharma and crop sciences giant Bayer (ETR: BAYN) and Orion Corp (Nasdaq Helsinki: ORNAV) have agreed to start a Phase …
New FDA expanded access guidelines spell trouble for Sarepta
June 2, 2016Medical Communications, Research and Development, Sales and Marketing Duchenne Muscular Dystrophy, Eteplirsen, FDA, compassionate grounds, sarepta
New guidelines intended to streamline the process of expanded access to medicines by the US Food and Drug Administration (FDA) …
Biogen Alzheimer’s treatment accepted into EMA’s PRIME scheme
June 2, 2016Research and Development, Sales and Marketing Alzheimer's, Biogen, EMA, PRIME, accelerated approval
Biogen (NASDAQ: BIIB) has announced that the European Medicines Agency (EMA) has accepted its investigational treatment for Alzheimer’s disease, aducanumab, …
Global oncology market to reach $150 billion by 2020, says IMS Health
June 2, 2016Research and Development IMS Health, annual global growth, cancer drugs, oncology
Global sales of oncology drugs rose to $107 billion in 2015, according to a new IMS Health report, with growth …
AstraZeneca licenses gout drug Zurampic to Grünenthal in Europe and Latin America
June 2, 2016Business Services, Manufacturing and Production, Sales and Marketing AstraZeneca, Grunenthal, Licencing, Zurampic, gout, sales
UK drugmaker AstraZeneca (LSE: AZN) on Thursday said it has entered into a licensing agreement worth up to $230 million …
Novartis’ Afinitor gets EU approval to treat cancerous gastrointestinal or lung tumors
June 2, 2016Research and Development, Sales and Marketing Afinitor, Cancer, European Commission, Novartis, regulation
Swiss drugmaker Novartis (VTX: NOVN) on Thursday said the European Commission has approved its Afinitor (everolimus) to treat cancerous gastrointestinal …
Phase III trials to start in Novartis/Genmab multiple sclerosis collaboration
June 2, 2016Research and Development Arzerra, Genmab, Novartis, multiple sclerosis, ofatumumab, phase III
Genmab (NASDAQ: GEN) has announced that its collaboration partner, Novartis, is set to initiate Phase III trials for ofatumumab in …
Sanofi looks to set date for showdown with Medivation shareholders
June 2, 2016Sales and Marketing Medivation, Sanofi, hostile, record date, shareholders, takeover
Sanofi (NYSE: SNY) has announced that it has attempted to fix a record date with Medivation (NASDAQ: MDVN) where the …
Janssen says its Trevicta gets European regulatory approval as maintenance therapy for Schizophrenia
June 2, 2016Medical Communications, Research and Development European Commission, Janssen, Trevicta, schizophrenia
Janssen said the European Commission has approved its Trevicta (paliperidone palmitate, a 3‑monthly injection) as maintenance treatment of schizophrenia. Trevicta …
Latest content
Pharma sees climate disruption as growing supply-chain risk
Manchester NHS-MHRA partnership to test new technologies in real-world care
